ZA200905730B - Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides and use thereof - Google Patents

Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides and use thereof

Info

Publication number
ZA200905730B
ZA200905730B ZA200905730A ZA200905730A ZA200905730B ZA 200905730 B ZA200905730 B ZA 200905730B ZA 200905730 A ZA200905730 A ZA 200905730A ZA 200905730 A ZA200905730 A ZA 200905730A ZA 200905730 B ZA200905730 B ZA 200905730B
Authority
ZA
South Africa
Prior art keywords
naphthyridinamides
dihydro
aryl
substituted
Prior art date
Application number
ZA200905730A
Other languages
English (en)
Inventor
Lars Baerfacker
Peter Kolkhof
Karl-Heinz Schlemmer
Rolf Grosser
Adam Nitsche
Martina Klein
Klaus Muenter
Barbara Albrecht-Kuepper
Elke Hartmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39512753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200905730(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200905730B publication Critical patent/ZA200905730B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
ZA200905730A 2007-02-27 2009-08-18 Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides and use thereof ZA200905730B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007009494A DE102007009494A1 (de) 2007-02-27 2007-02-27 Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung

Publications (1)

Publication Number Publication Date
ZA200905730B true ZA200905730B (en) 2010-10-27

Family

ID=39512753

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905730A ZA200905730B (en) 2007-02-27 2009-08-18 Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides and use thereof

Country Status (46)

Country Link
US (2) US8436180B2 (pt-PT)
EP (1) EP2132206B1 (pt-PT)
JP (2) JP5367586B2 (pt-PT)
KR (1) KR101614164B1 (pt-PT)
CN (1) CN101641352B (pt-PT)
AR (1) AR065463A1 (pt-PT)
AU (1) AU2008221071B2 (pt-PT)
BR (2) BR122020008544B8 (pt-PT)
CA (1) CA2679232C (pt-PT)
CL (1) CL2008000502A1 (pt-PT)
CO (1) CO6220951A2 (pt-PT)
CR (1) CR10976A (pt-PT)
CU (1) CU23874B1 (pt-PT)
CY (2) CY1116455T1 (pt-PT)
DE (1) DE102007009494A1 (pt-PT)
DK (1) DK2132206T3 (pt-PT)
DO (1) DOP2009000205A (pt-PT)
EC (1) ECSP099581A (pt-PT)
ES (1) ES2540803T3 (pt-PT)
FR (1) FR22C1017I2 (pt-PT)
GT (1) GT200900230A (pt-PT)
HK (1) HK1140194A1 (pt-PT)
HN (1) HN2009001597A (pt-PT)
HR (1) HRP20150702T1 (pt-PT)
HU (2) HUE026441T2 (pt-PT)
IL (1) IL200060A (pt-PT)
JO (1) JO3018B1 (pt-PT)
LT (1) LTPA2022512I1 (pt-PT)
MA (1) MA31245B1 (pt-PT)
MX (1) MX2009008701A (pt-PT)
MY (2) MY150748A (pt-PT)
NL (1) NL301192I2 (pt-PT)
NO (1) NO2022013I1 (pt-PT)
NZ (1) NZ579230A (pt-PT)
PA (1) PA8770101A1 (pt-PT)
PE (1) PE20090724A1 (pt-PT)
PL (1) PL2132206T3 (pt-PT)
PT (1) PT2132206E (pt-PT)
SA (1) SA08290071B1 (pt-PT)
SI (1) SI2132206T1 (pt-PT)
TN (1) TN2009000318A1 (pt-PT)
TW (2) TWI474821B (pt-PT)
UA (1) UA102065C2 (pt-PT)
UY (3) UY38953A (pt-PT)
WO (1) WO2008104306A2 (pt-PT)
ZA (1) ZA200905730B (pt-PT)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
SG11201401816SA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP2932289A1 (en) * 2012-12-17 2015-10-21 General Electric Company In-vitro magnetic resonance detection of a target substance
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
CN103193704B (zh) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-羟基-4-氨基-5-甲基吡啶杂环化合物
DK3160948T3 (en) 2014-06-30 2019-02-18 Astrazeneca Ab BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS
US10059707B2 (en) * 2014-08-01 2018-08-28 Bayer Pharma AG Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CA2995949A1 (en) * 2015-08-21 2017-03-02 Bayer Pharma Aktiengesellschaft Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods
PE20180554A1 (es) * 2015-08-21 2018-04-02 Bayer Pharma AG Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico
JP2018523698A (ja) * 2015-08-21 2018-08-23 バイエル・ファルマ・アクティエンゲゼルシャフト （４ｓ）−および（４ｒ）−４−（４−シアノ−２−メトキシフェニル）−５−エトキシ−２，８−ジメチル−１，４−ジヒドロ−１，６−ナフチリジン−３−カルボキサミドの代謝産物の調製方法およびその使用
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
UY36999A (es) 2015-12-02 2017-06-30 Syngenta Participations Ag Derivados de aryl oxadiazol fungicidas
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2018153898A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
US11447481B2 (en) 2017-06-02 2022-09-20 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
CN109721536B (zh) * 2017-10-27 2020-11-24 广东东阳光药业有限公司 苯基取代的稠合三环类化合物及其用途
EP3560922A1 (de) 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
JP7457658B2 (ja) * 2018-05-22 2024-03-28 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 フェニル置換ジヒドロナフチリジン化合物及びその使用
CN110917195A (zh) * 2018-08-20 2020-03-27 山西惠尔健生物科技有限公司 肌松剂阿库氯铵（Alcuronium chloride）可作为抗心律失常药物
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar
CN113474332A (zh) 2019-03-05 2021-10-01 拜耳公司 使用中间体化合物2-氯-5-甲基-4-吡啶胺从2-氯-5-甲基-4-硝基-吡啶-1-氧化物开始合成4-氨基-5-甲基-1h-吡啶-2(1h)-酮（用于合成mr拮抗剂非奈利酮的中间体化合物）的方法
KR20210135509A (ko) 2019-03-05 2021-11-15 바이엘 악티엔게젤샤프트 4-아미노-5-메틸피리돈을 제조하는 방법
PE20221414A1 (es) * 2019-10-17 2022-09-20 Bayer Ag Procedimiento para preparar esteres aciloximetilicos del acido (4s)-(4-ciano-2- metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilico
JOP20220091A1 (ar) * 2019-10-17 2023-01-30 Bayer Ag عملية لتحضير 2-سيانو إثيل (4s)-4-(4-سيانو-2-مثوكسي فنيل)-5-هيدروكسي-2، 8-ثنائي مثيل-1، 4-ثنائي هيدرو-1، 6- نفثيريدين-3- كربوكسيلات باستبانة مركبات راسيمية بواسطة إسترات حمض طرطريك صنوية فراغية
CR20220157A (es) * 2019-10-17 2022-06-02 Bayer Ag Procedimiento para preparar (4s)–4–(4–ciano–2–metoxi–fenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo mediante separación de racematos utilizando ésteres diastereoméricos de ácido tartárico
US20240150357A1 (en) * 2019-10-17 2024-05-09 Bayer Aktiengesellschaft Photochemical process for producing (4r,4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide
EP4118235A1 (en) 2020-03-11 2023-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4138826A1 (en) 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP3900722A1 (en) 2020-04-22 2021-10-27 Bayer AG Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2021213486A1 (zh) * 2020-04-24 2021-10-28 东莞市东阳光新药研发有限公司 二氢萘啶类化合物的晶型及其用途
WO2021213493A1 (zh) * 2020-04-24 2021-10-28 东莞市东阳光新药研发有限公司 二氢萘啶类化合物的晶型及其用途
WO2021254896A1 (en) 2020-06-16 2021-12-23 Bayer Aktiengesellschaft Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction
WO2022214206A1 (en) 2021-04-08 2022-10-13 Bayer Aktiengesellschaft Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
EP4373476A1 (en) * 2021-07-21 2024-05-29 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea
EP4403555A1 (en) 2021-09-18 2024-07-24 Tuojie Biotech (Shanghai) Co., Ltd. Substituted 1,4-dihydro-1,6-naphthyridine amide and use thereof
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
WO2023205164A1 (en) * 2022-04-18 2023-10-26 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
EP4286368A1 (de) 2022-05-31 2023-12-06 Bayer Aktiengesellschaft Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril
WO2024022481A1 (zh) * 2022-07-29 2024-02-01 苏中药业集团股份有限公司 苯基取代的二氢萘啶类化合物及其制备与用途
WO2024110523A1 (en) 2022-11-23 2024-05-30 Bayer Aktiengesellschaft Treatment of chronic kidney disease in type i diabetes mellitus
WO2024126694A1 (en) 2022-12-16 2024-06-20 Bayer Aktiengesellschaft Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
WO2024193455A1 (zh) * 2023-03-17 2024-09-26 江苏恒瑞医药股份有限公司 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法
CN116715664A (zh) * 2023-06-12 2023-09-08 常州制药厂有限公司 一种非奈利酮关键中间体的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3327650A1 (de) 1983-07-30 1985-02-14 Gödecke AG, 1000 Berlin 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von gefaesserkrankungen
US4698341A (en) * 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
DE3502831A1 (de) 1985-01-29 1986-07-31 Gödecke AG, 1000 Berlin 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung
US4760081A (en) * 1984-08-25 1988-07-26 Goedecke Aktiengesellschaft 1,6-naphthyridine derivatives useful for treating diseases of the blood vessels
DE3431303A1 (de) * 1984-08-25 1986-02-27 Goedecke Ag 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
IL75987A (en) 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
CA2385908A1 (en) 2000-08-02 2002-02-07 Abbott Laboratories Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
DE102004012365A1 (de) 2004-03-13 2005-09-29 Bayer Healthcare Ag Substituierte Dihydropyridine
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
US20090298872A1 (en) 2004-12-13 2009-12-03 Irm Llc Compounds and compositions as modulators of steroidal receptors and calcium channel activities
CN101227857B (zh) 2005-06-29 2011-10-19 电脑医师有限公司 具有导电桥的传感器组件
DE102005034264A1 (de) 2005-07-22 2007-02-01 Bayer Healthcare Ag 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung
DE102006026583A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102006026585A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung

Also Published As

Publication number Publication date
IL200060A0 (en) 2010-04-15
BRPI0808098B8 (pt) 2021-05-25
CY2022022I2 (el) 2023-01-05
BR122020008544B1 (pt) 2021-02-17
US20100136142A1 (en) 2010-06-03
TWI474821B (zh) 2015-03-01
NZ579230A (en) 2012-04-27
UY38952A (es) 2021-08-31
MX2009008701A (es) 2009-08-27
FR22C1017I1 (fr) 2022-06-17
BR122020008544B8 (pt) 2021-07-27
PE20090724A1 (es) 2009-07-17
HRP20150702T1 (hr) 2015-08-14
RU2470932C2 (ru) 2012-12-27
CA2679232C (en) 2016-07-05
TN2009000318A1 (en) 2010-12-31
US20140100243A1 (en) 2014-04-10
HUS2200015I1 (hu) 2022-06-28
CN101641352A (zh) 2010-02-03
FR22C1017I2 (fr) 2023-02-03
TWI415608B (zh) 2013-11-21
JP5367586B2 (ja) 2013-12-11
UY38953A (es) 2021-08-31
NO2022013I1 (en) 2022-05-06
CN101641352B (zh) 2013-11-20
EP2132206A2 (de) 2009-12-16
GT200900230A (es) 2011-11-29
IL200060A (en) 2016-07-31
CY2022022I1 (el) 2023-01-05
ES2540803T3 (es) 2015-07-13
CO6220951A2 (es) 2010-11-19
CL2008000502A1 (es) 2008-06-13
UA102065C2 (en) 2013-06-10
AU2008221071A1 (en) 2008-09-04
BRPI0808098B1 (pt) 2020-08-04
PL2132206T3 (pl) 2015-08-31
CY1116455T1 (el) 2017-03-15
JP2010519232A (ja) 2010-06-03
DOP2009000205A (es) 2010-02-28
JP2014012678A (ja) 2014-01-23
WO2008104306A2 (de) 2008-09-04
US8436180B2 (en) 2013-05-07
US9051316B2 (en) 2015-06-09
HUE026441T2 (en) 2016-06-28
BRPI0808098A2 (pt) 2014-06-17
NL301192I2 (nl) 2022-12-07
HK1140194A1 (en) 2010-10-08
RU2009135659A (ru) 2011-04-10
PT2132206E (pt) 2015-08-04
ECSP099581A (es) 2009-09-29
TW201340968A (zh) 2013-10-16
PA8770101A1 (es) 2009-05-15
CR10976A (es) 2010-01-13
UY30931A1 (es) 2008-09-30
CA2679232A1 (en) 2008-09-04
AR065463A1 (es) 2009-06-10
TW200843755A (en) 2008-11-16
DK2132206T3 (en) 2015-07-06
CU23874B1 (es) 2013-04-19
EP2132206B1 (de) 2015-04-01
MY150748A (en) 2014-02-28
MY176873A (en) 2020-08-25
SA08290071B1 (ar) 2012-11-03
JP5752754B2 (ja) 2015-07-22
LTPA2022512I1 (pt-PT) 2022-07-11
AU2008221071B2 (en) 2014-01-16
DE102007009494A1 (de) 2008-08-28
HN2009001597A (es) 2012-01-16
WO2008104306A3 (de) 2009-03-19
KR101614164B1 (ko) 2016-04-20
MA31245B1 (fr) 2010-03-01
SI2132206T1 (sl) 2015-08-31
KR20090129992A (ko) 2009-12-17
CU20090148A7 (es) 2011-04-26
JO3018B1 (ar) 2016-09-05

Similar Documents

Publication Publication Date Title
HUS2200015I1 (hu) Szubsztituált 4-aril-1,4-dihidro-1,6-naftiridinamidok és alkalmazásuk
HK1199031A1 (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof 2--5--1,2,4-
EP2124550A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE
ZA200905564B (en) Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
SI2217578T1 (sl) (1,2,4)triazolo(1,5-a)piridinske in (1,2,4)triazolo(1,5-c)pirimidinske spojine in njihova uporaba
EP2253625A4 (en) PYRIDAZINONES, PREPARATION AND USE THEREOF
IL206127A0 (en) Azolylmethyloxiranes, use thereof and agents containing the same
IL208220A0 (en) Substituted imidazoquinolines, compositions comprising the same and uses thereof
HK1131140A1 (en) Substituted prolinamides, and the use thereof
ZA201005202B (en) Azabicyclic carboxamide derivatives,preparation thereof and theapeutic use thereof
IL218490A0 (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
GB0616111D0 (en) Agents, methods and uses
EP2139478A4 (en) CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
EP2195328A4 (en) PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
EP2283005A4 (en) CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF
GB0706077D0 (en) Methods, Compositions and uses thereof
EP2351732A4 (en) NEW RAMALINE CONNECTION AND ITS USE
GB0719592D0 (en) Compound, use and method
IL208168A0 (en) Tetrahydroisoquinoline derivatives, compositions comprising the same and use thereof
HRP20160578T1 (hr) Supstituirani furankarboksamidi i njihova upotreba
GB0703763D0 (en) Bone-replacement materials,methods and devices
EP2192122A4 (en) Dithiolopyrrolone compounds and their preparation and use
PL2026863T3 (pl) Jednostka podająca i sposób podawania
GB0719834D0 (en) Compounds, method and use